Health-tech startups need patience; deep-tech’s in favour now: Endiya Partners’ Ramesh Byrapaneni
Synopsis
Some startups fail due to excessive focus on achieving rapid growth at any cost and attaining unicorn status, says Ramesh Byrapaneni, managing director, Endiya Partners. Speaking to ET Prime, he discusses why investors are getting attracted to deep-tech firms, and his take on the ventures from his portfolio that are likely to become big in near future.
Cardiologist and entrepreneur-turned-venture investor Dr Ramesh Byrapaneni is the managing director of Endiya Partners. He has spearheaded the firm’s investments in SigTuple, EyeStem, Sugar.fit, AquaExchange among other startups. In July 2023, Endiya made a Series B investment in Zluri, which raised USD20 million. Endiya Partners has USD100 million under management and counts HR software venture DarwinBox and health and wellness platform
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
For all the latest Technology News Click Here
For the latest news and updates, follow us on Google News.